Join
Live feed
·
PRReleasevia Quantisnow
GE HealthCare Technologies Inc. logo

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

ByQuantisnow·Wall Street's wire, on your screen.
GEHC· GE HealthCare Technologies Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GEHC (GE HealthCare Technologies Inc.) and more on Quantisnow.